Delivery Considerations of Cognitive Processing Therapy for PTSD

Sponsor
VA Salt Lake City Health Care System (U.S. Fed)
Overall Status
Active, not recruiting
CT.gov ID
NCT04765319
Collaborator
(none)
100
1
108
0.9

Study Details

Study Description

Brief Summary

Review treatment outcomes of modifications to standard delivery of CPT for PTSD that are delivered as routine care at in VA outpatient clinic.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: CPT for PTSD

Detailed Description

Background and Introduction Cognitive Processing Therapy (CPT) is an evidenced based psychotherapy for PTSD. It is considered a first line treatment and has ample evidence supporting it's effectiveness (ISTSS and VA/DOD clinical practice guidelines). This therapy is manualized and a framework is provided to ensure consistent delivery. Additionally, the VA Office of Mental Health Operations sponsors training and dissemination of CPT throughout the VA system and the PI of this study is a trainer and consultant of this therapy. Flexibility exists in the protocol and CPT can be delivered in unorthodox modalities such as telehealth (Moreland et al, 2015) and on compressed time schedules (Held et al, 2020; Bryan et al, 2018). While the literature supports the effectiveness of these interventions in unique settings, no known studies have looked at outcome data of real-world outpatient clinics. The PTSD Clinical Team provides CPT as part of it's standard care with a variety of adaptations. The team practices measurement based care and routinely collects self-report symptom inventories to track patient progress. This study aims to use data collected as part of standard care in this clinic to evaluate the effectiveness of these treatment adaptations in this setting.

Purpose and Objectives The purpose of this study is to explore the impact of how CPT for PTSD is delivered. Initial areas of review will include in person vs. telehealth delivery and timing (daily vs. weekly).

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Delivery Considerations of Cognitive Processing Therapy for PTSD
Actual Study Start Date :
Jan 1, 2016
Actual Primary Completion Date :
Aug 1, 2020
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Vets

Veterans receiving care from the PTSD Clinical Team at the Salt Lake City VAMC. All participants are adults with a diagnosis of PTSD. This study plans on reviewing data collected as part of standard clinical practices. The study will have no impact on the treatment provided to the patient.

Behavioral: CPT for PTSD
Evidence based psychotherapy for PTSD

Outcome Measures

Primary Outcome Measures

  1. PTSD Checklist 5 [Through study completion, an average of 12 sessions (3 months)]

    Self report PTSD symptom inventory

Secondary Outcome Measures

  1. PHQ-9 [Through study completion, an average of 12 sessions (3 months)]

    Self report depression symptom inventory

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • PTSD diagnosis

  • Veterans eligible for VA care

  • Treatment seeking Veterans

Exclusion Criteria:
  • PTSD not priority of treatment due to comorbidity, safety, etc. All patients that would be treated for PTSD in outpatient clinic are included.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Salt Lake City VAMC Salt Lake City Utah United States 84148

Sponsors and Collaborators

  • VA Salt Lake City Health Care System

Investigators

  • Principal Investigator: Harrison R Weinstein, PhD, VA Salt Lake City

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Harrison R Weinstein, Principal Invesigator, VA Salt Lake City Health Care System
ClinicalTrials.gov Identifier:
NCT04765319
Other Study ID Numbers:
  • IRB_00133139
First Posted:
Feb 21, 2021
Last Update Posted:
Feb 21, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Feb 21, 2021